(Date:12/2/2009)... NEW YORK, Dec. 2 Reportlinker.com announces ... available in its catalogue: ,, Carbondioxide ... ,, http://www.reportlinker.com/p0164368/Carbondioxide-Incubators---A-Global-Market-Perspective.html ,, Incubators ... microbiology, genetics, cancer, research, and other applications ...
(Date:12/2/2009)... Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ: ... previously announced unit offering, the underwriters have exercised in ... units. Each unit is comprised of one common share ... was sold at a price of US$3.00 per unit. ...
(Date:12/2/2009)... today announced data presentations on its novel oral JAK2 ... Annual Meeting and Exposition in New Orleans. ,, Data ... Phase 1 dose-escalation trial of SB1518 detailing its safety, ... from 100 to 600 mg. These doses were administered ...
(Date:12/2/2009)... The Scientist, a leading scientific magazine covering the life sciences, ... “Top 10 Innovations of 2009. , ... ... EMCCD camera from Photometrics ®, a designer and ...
Breaking Biology Technology:Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 2The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 3... April 23 STAAR Surgical,Company (Nasdaq: STAA ... invasive ophthalmic products, today announced very strong,participation in ... the Company,s,Visian ICL(TM) (Implantable Collamer Lens). The first ... My Website Compels Patients to Call,Me," is part ...
... Pipeline of Oncology Products Including Novel Nucleoside Analogue; New ... ... MacroChem Corporation (OTC,Bulletin Board: MACM) announced today that on April ... company,developing and commercializing novel therapeutics, with a portfolio of,clinical stage ...
... patients treated with PBI-1402 did not require blood ... ... ProMetic Life Sciences Inc.,(TSX: PLI) ("ProMetic") announces that oral PBI-1402 demonstrates,significant ... red blood cell ("RBC") transfusion., Only 2 patients out of ...
Other Biology Technology:More Than 700 Physicians and Administrators Participate in the Visian ICL Growth Program(TM) Launch 2More Than 700 Physicians and Administrators Participate in the Visian ICL Growth Program(TM) Launch 3MacroChem Acquires Virium Pharmaceuticals 2MacroChem Acquires Virium Pharmaceuticals 3MacroChem Acquires Virium Pharmaceuticals 4MacroChem Acquires Virium Pharmaceuticals 5Oral PBI-1402 Demonstrates Significant Activity in Chemotherapy-Induced Anemia Phase II Clinical Trial 2Oral PBI-1402 Demonstrates Significant Activity in Chemotherapy-Induced Anemia Phase II Clinical Trial 3... For the efficient enrichment of functional ... or cell culture. The isolated ER ... and metabolic pathway analysis. Metabolic abnornalities ... in children, cystic fibrosis and many ...
Plasmid expressing PLAP reporter gene....
Plasmid expressing the LacZ reporter gene....
Human SEAP ORF, provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
Biology Products: